Pyrogallol
Based on 4 publication(s) in Google Scholar
Pyrogallol is a polyphenol compound, which has anti-fungal and anti-psoriatic properties. Pyrogallol is a reductant that is able to generate free radicals, in particular superoxide anions.
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 87-66-1
- Formula: C6H6O3
- Molecular Weight:126.11
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pyrogallol
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Microbial Metabolite |
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | IC50 |
>5 μM
Compound: 7f ; pyrogallol
|
Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)
Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)
|
[PMID: 9371243] |
Pyrogallol (PG) is a reductant that is able to generate free radicals, in particular superoxide anions (O2?-), so has frequently been used as a photographic developing agent and in the hair dying industry. Pyrogallol inhibits Calu-6 and A549 lung cancer cell growth via apoptosis and depletion of glutathione (GSH). Pyrogallol (PG) induces apoptosis in lung cancer cells via the overproduction of O2?- and affects mitogen activated protein kinases (MAPKs) in these cells[1]. The effect of Pyrogallol on human pulmonary fibroblast (HPF) cell viability and necrotic cell death is examined. For these experiments, 0, 50 or 100 μM Pyrogallol is used to differentiate the levels of cell viability inhibition or death with or without a given MAPK inhibitor. Treatment with 50 and 100 μM Pyrogallol decreases HPF viability by ~40 and 65% at 24 h, respectively. Treatment with an MEK inhibitor slightly enhances the inhibition of cell viability in 50 μM Pyrogallol-treated HPF cells, whereas treatment with a p38 inhibitor mildly attenuates the inhibition of viability. In 100 μM Pyrogallol-treated HPF cells, all the MAPK inhibitors increase the inhibition of viability to a certain extent, with treatment with the p38 inhibitor alone augmenting HPF control cell viability. Necrotic cell death is determined by measuring lactate dehydrogenase (LDH) release from cells. While treatment with 50 μM Pyrogallol does not affect LDH release from HPF cells, 100 μM Pyrogallol significantly increases LDH release[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 87-66-1
-
Appearance Solid
-
Molecular Weight 126.11
-
Formula C6H6O3
-
Color White to off-white
-
SMILES
OC1=CC=CC(O)=C1O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
MedComm
Pyrogallol protects against influenza A virus-triggered lethal lung injury by activating the Nrf2-PPAR-γ-HO-1 signaling axis. [Abstract]2024 Apr 12;5(4):e531. PMID: 38617435 -
Free Radic Biol Med
Pyrogallol enhances therapeutic effect of human umbilical cord mesenchymal stem cells against LPS-mediated inflammation and lung injury via activation of Nrf2/HO-1 signaling. [Abstract]2022 Oct:191:66-81. PMID: 36028178 -
-
Plants
Anti-Inflammatory Effect of Meriania hexamera Sprague by Targeting Syk Kinase in NF-κB Signaling. [Abstract]2023 Aug 24;12(17):3044. PMID: 37687291
Solvent & Solubility
DMSO : ≥ 100 mg/mL (792.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (396.48 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (19.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (19.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 130 mg/mL (1030.84 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
Briefly, 5×103 HPF cells per well in 96-well microtiter plates are exposed to 0, 50 or 100 µM Pyrogallol with or without each MAPK inhibitor at 37°C for 24 h. Changes in cell viability induced by Pyrogallol and/or a given MAPK inhibitor are determined by measuring the MTT; dye absorbance[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 7.9295 mL | 39.6476 mL | 79.2952 mL | 198.2381 mL |
| 5 mM | 1.5859 mL | 7.9295 mL | 15.8590 mL | 39.6476 mL | |
| 10 mM | 0.7930 mL | 3.9648 mL | 7.9295 mL | 19.8238 mL | |
| 15 mM | 0.5286 mL | 2.6432 mL | 5.2863 mL | 13.2159 mL | |
| 20 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | 9.9119 mL | |
| 25 mM | 0.3172 mL | 1.5859 mL | 3.1718 mL | 7.9295 mL | |
| 30 mM | 0.2643 mL | 1.3216 mL | 2.6432 mL | 6.6079 mL | |
| 40 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL | 4.9560 mL | |
| 50 mM | 0.1586 mL | 0.7930 mL | 1.5859 mL | 3.9648 mL | |
| 60 mM | 0.1322 mL | 0.6608 mL | 1.3216 mL | 3.3040 mL | |
| 80 mM | 0.0991 mL | 0.4956 mL | 0.9912 mL | 2.4780 mL | |
| 100 mM | 0.0793 mL | 0.3965 mL | 0.7930 mL | 1.9824 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Pyrogallol Related Classifications
HY-N1579 Related Classifications
Powered by Bioz